LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
28 funds hold it · Insiders net selling
Net selling: insiders sold $41.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 2, 2026
Period ending
Sep 30, 2026
Earnings per share
-$2.38 expected
Estimates as of Nov 10, 2026
EPS expected
$5.16 to $8.78
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 2, 2026 | -$3.88est. -$2.38 | -63.36%miss | $1.24BSEC filing | +10.4%from $1.13B |
| Jun 30, 2026Reported Aug 3, 2026 | $5.71est. $6.18 | -7.54%miss | $1.21BSEC filing | +15.5%from $1.05B |
| Mar 31, 2026Reported May 5, 2026 | $6.34est. $4.66 | +36.18%beat | $1.07BSEC filing | +19.1%from $897.8M |
| Dec 31, 2025Reported Feb 24, 2026 | $6.64est. $6.51 | +2.05%beat | $1.20BAlpha Vantage | +10.1%from $1.09B |
| Sep 30, 2025Reported Nov 5, 2025 | $6.99est. $4.80 | +45.63%beat | $1.13BSEC filing | +6.7%from $1.05B |
| Jun 30, 2025Reported Aug 5, 2025 | -$8.25est. -$6.25 | -32.00%miss | $1.05BSEC filing | +2.1%from $1.02B |
| Mar 31, 2025Reported May 6, 2025 | $1.68est. $4.66 | -63.95%miss | $897.8MSEC filing | -0.5%from $902.0M |
| Dec 31, 2024Reported Feb 25, 2025 | $6.60est. $5.81 | +13.58%beat | $1.09BAlpha Vantage | +7.5%from $1.01B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.20B | $1.07B | $1.21B | $1.24B |
| Cost of what it sold | $24.6M | $306.4M | $116.4M | $110.6M |
| Gross profit | $1.17B | $762.5M | $1.09B | $1.13B |
| What it spent | ||||
| Research and development | $171.4M | $134.1M | $207.5M | $211.9M |
| Sales and admin | $406.2M | $352.7M | $389.2M | $407.9M |
| Other operating costs | -$313.5M | $61.9M | $247.0M | $926.0M |
| Total operating expenses | $264.1M | $548.7M | $843.7M | $1.55B |
| What was left | ||||
| Operating profit | $909.2M | $213.8M | $248.2M | -$413.4M |
| Interest on debt | $45.4M | $63.3M | $37.1M | $45.5M |
| Profit before tax | $208.3M | $299.2M | $211.0M | -$458.9M |
| Tax | $4.9M | $6.1M | $18.1M | $24.5M |
| Net profit | $203.5M | $293.1M | $192.8M | -$483.4M |
| EBITDA | $432.9M | $543.9M | $427.2M | -$234.5M |
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Jazz Pharmaceuticals (JAZZ) Faces A Fresh Valuation Test Following Mixed Earnings And Buyback
NeutralNov 12Price-Driven Insight from (JAZZ) for Rule-Based Strategy
BullishNov 12At Jazz Pharmaceuticals, Bruce C Cozadd Chooses To Exercise Options, Resulting In $9.46M
Leans bullishNov 11Bernstein cuts Jazz Pharmaceuticals stock price target on Zepzelca outlook By Investing.com
Leans bearishNov 9Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 7 November
NeutralNov 7Form 144 JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY For: 7 November
NeutralNov 7Form 4 Jazz Pharmaceuticals plc: Patricia Carr (SVP, Chief Accounting Officer) For: 4 November
NeutralNov 7Form 4 Jazz Pharmaceuticals plc: Patricia Carr (SVP, Chief Accounting Officer) For: 4 November
NeutralNov 7
